Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Krazati

- PMLiVE

Bristol Myers Squibb announces new $2.3bn campus in the US

Texas has been chosen as the site for a new, state-of-the-art multi-modal manufacturing campus

- PMLiVE

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

- PMLiVE

Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate

The drug showed improvements in overall survival and progression-free survival in two cancers

- PMLiVE

Bristol Myers Squibb evolves and expands multiple myeloma programme

Created in 2016, the Standing in the Gaap programme aims to advance more equitable care

- PMLiVE

BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma

This type of cancer is the most common one diagnosed in teenagers

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis

Sotyktu is the first TYK2 inhibitor approved for active psoriatic arthritis

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

- PMLiVE

BMS announces affordable drug price agreement with US government

The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid

- PMLiVE

BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

- PMLiVE

BMS and Bain Capital launch new company to develop immunology therapies

The newly formed company has in-licensed five investigational immunology drugs from BMS

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links